
Telum Therapeutics raises €18 million to advance treatments for hospital-acquired infections
Telum Therapeutics, a Spanish BioTech company, today announced the successful completion of an €18 million Series A financing to advance its lead programme targeting hospital-acquired (HABP) and ve










